Litegrav's Simulated Microgravity Technology Provides New Insights into Breast Cancer Research

Tallinn, Estonia — January 23, 2023 — Litegrav, an innovator in the simulation of extreme environments for scientific research, partnered with the University of Pavia's department of Molecular Medicine to explore the effects of simulated microgravity on breast cancer cells. This collaboration aims to unlock new findings that could impact cancer treatment strategies both in space and on Earth.

Conducted with Litegrav’s 3D microgravity simulator research cube (MSCR), the study focused on two breast cancer cell lines: SKBR-3 (HER-2 overexpressing) and MCF-7 (low HER-2 expressing). The goal was to investigate growth behaviour and morphological changes under simulated space-like conditions.

“This is a great illustration of how simulated microgravity can offer new perspectives on cellular processes,” said Patrik Hollós, CEO of Litegrav. 

Researchers observed that simulated microgravity induced significant changes in the morphology of breast cancer cells, suggesting the activation of specific gene programs linked to tumor growth and metastasis. Understanding these cellular responses in space-like conditions could lead to the development of novel therapeutic strategies for combating cancer. 

The team observed alterations in the shape and structure of cancer cells under microgravity conditions and the activation of genetic pathways that can contribute to tumorigenesis or metastasis. Litegav’s simulated microgravity provided insights that could not be easily replicated under Earth’s gravity, highlighting the potential for new discoveries in cancer biology.

Litegrav’s MSCR technology played a pivotal role in ensuring optimal conditions for cell growth by simulating microgravity and supporting vital processes such as oxygen and nutrient transport. This technology is also expected to contribute to future research aimed at addressing the challenges faced by astronauts during long-term space missions.

About Litegrav
Litegrav provides scalable platforms for simulating microgravity and extreme biological environments, driving advancements in biotechnology, life sciences, and pharmaceutical research. The company’s technology supports groundbreaking research, both in space and on Earth, with the potential to address challenges in cancer treatment, microbial resistance, and more.

About the University of Pavia
The University of Pavia, founded in 1361, is one of Italy's oldest academic institutions, offering world-class research and education across a wide range of disciplines. The university’s Department of Molecular Medicine is at the forefront of bioscience research, focusing on cancer, molecular biology, and biotechnology.

Contact

‍For more information on Litegrav’s research and technology, visit www.litegrav.ai or contact info@litegrav.ai